{
  "id": "enwiki-001337927189",
  "slug": "mpd-75",
  "title": "MPD-75",
  "qid": "",
  "lead": "MPD-75, also known as 1-methyl-N-pyrrolidyllysergamide or as 1-methyllysergic acid pyrrolidide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is the 1-methyl derivative of lysergic acid pyrrolidide (LA-Pyr; LPD-824) and the N-pyrrolidide analogue of 1-methyl-LSD (MLD-41). Extensive metabolism of other 1-methylated lysergamides to their secondary amine derivatives, for instance methysergide (1-methylmethylergometrine) conversion into methylergometrine, has been observed.",
  "body": "MPD-75, also known as 1-methyl-N-pyrrolidyllysergamide or as 1-methyllysergic acid pyrrolidide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is the 1-methyl derivative of lysergic acid pyrrolidide (LA-Pyr; LPD-824) and the N-pyrrolidide analogue of 1-methyl-LSD (MLD-41). Extensive metabolism of other 1-methylated lysergamides to their secondary amine derivatives, for instance methysergide (1-methylmethylergometrine) conversion into methylergometrine, has been observed. ==Use and effects== MPD-75 was evaluated in humans and was found to produce partial LSD-like effects. It was reported to have had a faster onset and shorter duration compared to LSD. MPD-75 showed less than 5% of the potency of LSD in producing LSD-like effects, with a required dose of >20 μg/kg or >1.6 mg orally. According to another source however, MPD-75 had 7% of the potency of LSD in humans. For comparison, LA-Pyr (LPD-824) had approximately 10% of the potency of LSD and had more full LSD-like effects, while 1-methyl-LSD (MLD-41) had 33% of the potency of LSD and likewise produced full LSD-like effects. ==Interactions== ==Pharmacology== ===Pharmacodynamics=== In animal studies, MPD-75 had 4% of the toxicity of LSD in rabbits (presumably in terms of ), 0% of its pyretogenic activity in rabbits, and 130% of its antiserotonergic activity in the isolated rat uterus. ==History== MPD-75 was first described in the scientific literature by Albert Hofmann and colleagues by 1957. It has not been encountered as a designer drug as of 2020. ==See also== Substituted lysergamide Lysergic acid pyrrolidide (LA-Pyr; LPD-824) MLD-41 (1-methyl-LSD) MLA-74 (1-methyl-LAE) ==References== ==External links== MPD-75 - Isomer Design",
  "categories": [
    "100911280",
    "100989052",
    "106462793",
    "106462794",
    "107567720",
    "23118434",
    "23603337",
    "27236659",
    "37750075",
    "48128016",
    "50769796",
    "54374437",
    "63007578",
    "90894244"
  ],
  "license": "CC BY-SA 4.0",
  "source_uri": "https://en.wikipedia.org/w/index.php?oldid=1337927189",
  "content_hash": "",
  "created_at": null,
  "updated_at": 1770871924.0,
  "claims": [],
  "contradictions": [],
  "confidence": 0.6,
  "csl": {
    "id": "enwiki-001337927189",
    "type": "webpage",
    "title": "MPD-75",
    "author": [
      {
        "family": "Anticloud FZ LLE",
        "literal": "Anticloud FZ LLE"
      }
    ],
    "container-title": "encyclopegia.org",
    "publisher": "Anticloud FZ LLE",
    "publisher-place": "Dubai, United Arab Emirates",
    "URL": "https://encyclopegia.org/a/mpd-75",
    "issued": {
      "date-parts": [
        [
          2026,
          11,
          15
        ]
      ]
    },
    "accessed": {
      "date-parts": [
        [
          2026,
          11,
          15
        ]
      ]
    },
    "license": "CC BY-SA 4.0",
    "DOI": "eo1:enwiki-001337927189",
    "isBasedOn": "https://en.wikipedia.org/w/index.php?oldid=1337927189",
    "note": "Immutable snapshot enwiki-001337927189"
  }
}